Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class, seven times more potent than Fentanyl and at the same time offers various advantages in terms of safety and efficacy for chronic pain treatment with a transdermal system” says Labtec’s Managing Director, Dr. Ingo Lehrke.

Beginning with phase II clinical development Labtec is now willing to enter into a global development and licensing agreement with a strong and committed partner.

Company Information:
Labtec GmbH is a leading drug delivery company specialised on development of matrix-type transdermal and topical patches as well as fast dissolving oral films (Rapidfilms).

Contact:
Dr. Ingo Lehrke; Managing Director; Business Development & Licensing
Labtec GmbH | www.labtec-pharma.com | Raiffeisenstrasse 3a | D-40764 Langenfeld | Germany | T: +49 2173 9735-0


'"/>




Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27, 2017  Market Research presents an all-encompassing and one ... market titled ,Medical Fiber Optics Market: Global Industry Analysis and ... globally across the five key regions of North ... Europe , APAC and MEA which influence the ... optics market over the forecast period. In this report, Persistence ...
(Date:2/28/2017)... TRIANGLE PARK, N.C. , Feb. 28, 2017 ... that Martine Rothblatt , Ph.D., Chairman and Chief Executive ... on the company,s business at the Cowen and Company 37 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:2/28/2017)... 27, 2017  Clarivate Analytics marks the passing of one if its ... contributions to information science in the service of scientific and scholarly research. ... an indexing system that revolutionized the way researchers work with the literature, ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
Breaking Medicine News(10 mins):